Short Interest in FibroBiologics Inc. (NASDAQ:FBLG) Grows By 100.7%

FibroBiologics Inc. (NASDAQ:FBLG) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totaling 237,640 shares, a growth of 100.7% from the April 30th total of 118,414 shares. Based on an average daily trading volume, of 563,635 shares, the days-to-cover ratio is presently 0.4 days. Currently, 5.0% of the shares of the stock are short sold.

FibroBiologics Price Performance

FBLG stock traded down $0.04 on Monday, hitting $1.12. 90,128 shares of the company were exchanged, compared to its average volume of 295,362. The stock has a market capitalization of $5.84 million, a price-to-earnings ratio of -0.16 and a beta of 1.13. The business’s fifty day moving average is $1.80 and its two-hundred day moving average is $4.53. FibroBiologics has a twelve month low of $0.95 and a twelve month high of $19.80.

FibroBiologics (NASDAQ:FBLG) last issued its earnings results on Thursday, April 30th. The company reported ($1.33) earnings per share for the quarter, hitting the consensus estimate of ($1.33). Equities research analysts expect that FibroBiologics will post -4.41 earnings per share for the current year.

Analyst Ratings Changes

FBLG has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of FibroBiologics in a research report on Tuesday, April 21st. Wall Street Zen upgraded shares of FibroBiologics to a “sell” rating in a research report on Saturday, April 4th. Maxim Group lowered shares of FibroBiologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. HC Wainwright reissued a “buy” rating and set a $8.00 price target (up from $4.00) on shares of FibroBiologics in a research report on Thursday, April 16th. Finally, D. Boral Capital reissued a “hold” rating on shares of FibroBiologics in a report on Thursday, March 26th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $74.00.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Yorkville Advisors Global LP acquired a new stake in shares of FibroBiologics in the 3rd quarter worth approximately $278,000. Landscape Capital Management L.L.C. acquired a new position in FibroBiologics in the 3rd quarter valued at approximately $191,000. Geode Capital Management LLC grew its position in FibroBiologics by 20.7% in the fourth quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock worth $78,000 after acquiring an additional 59,813 shares in the last quarter. Renaissance Technologies LLC grew its position in FibroBiologics by 287.3% in the fourth quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock worth $52,000 after acquiring an additional 171,800 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of FibroBiologics during the 4th quarter worth $34,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.